Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06262347 · ClinicalTrials.gov registry record · NA

Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD

A NA study, sponsored by T. John Winhusen, PhD.

Completed
Registry status
NA
Development phase
131
Enrollment target

NCT06262347: Completed NA study, sponsored by T. John Winhusen, PhD.

NCT06262347 is a NA study that has completed, run by T. John Winhusen, PhD. The registered enrollment target is 131 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06262347, a NA study, has completed, sponsored by T. John Winhusen, PhD.

COMPLETED
Registry status
NA
Development phase
131 participants
Enrollment target

Study Summary

The primary objective of this study is to evaluate the ability of TOME to increase Medication for Opioid Use Disorder (MOUD) and opioid-overdose knowledge in pregnant and postpartum persons.

Primary Outcome

This outcome is measured by the Opioid Overdose and Treatment Awareness Survey (OOTAS) knowledge evaluation: MOUD knowledge, potential score of 0-10; higher score indicates more knowledge. Values are converted to a percentage of correct answers from 0-100% where higher percentages mean more knowledge.

Interventions

  • BEHAVIORAL Control
  • BEHAVIORAL Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2024-06-13
Est. Completion 2024-11-11
Phase NA
T. John Winhusen, PhD

5 total trials

What the finished NCT06262347 record still lists

NCT06262347 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.

NCT06262347 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06262347 about?

NCT06262347 is a clinical study titled "Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD". The primary objective of this study is to evaluate the ability of TOME to increase Medication for Opioid Use Disorder (MOUD) and opioid-overdose knowledge in pregnant and postpartum persons.

What is the current status of trial NCT06262347?

This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2024-06-13. Estimated completion is 2024-11-11.

What interventions are being tested in trial NCT06262347?

The interventions under investigation include: Control (BEHAVIORAL), Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06262347?

This trial is sponsored by T. John Winhusen, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06262347's enrollment target sits among peer trials

131 732nd of 2000 higher than 1,268 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03051464 · 131 participants · Phase 2

    No Surgery Trial / Two Dose-escalation Strategies

  • NCT04301843 · 131 participants · Phase 2

    Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  • NCT04748549 · 131 participants · NA

    Intraoperative VR for Older Patients Undergoing TKA

  • NCT05951179 · 131 participants · Phase 2

    Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06262347, the US trial registry maintained by the National Library of Medicine. NCT06262347 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.